Market data as of Jun 3, 2026
Analysis for Gilead Sciences is being prepared
Our research team is working on a comprehensive fundamental analysis. Check back soon — financial charts and valuation models will appear here.
Detailed Charts
Gilead Sciences Quarterly Performance
Quarterly revenue and net income with a weekly share-price overlay
Upgrade to see the full 5 years (20 quarters) of quarterly data.
How to Read Quarterly Performance
Quarterly revenue and net income are Gilead Sciences's most recent three-month results. Each bar shows net income nested inside revenue, since profit is the slice of revenue left after all costs; the taller the green portion relative to the blue, the more of each sales dollar reached the bottom line. A bar below zero is a quarterly loss.
For a long-term view, compare each quarter with the same quarter a year earlier (year-over-year), not with the previous quarter — sequential change is mostly seasonality (for many businesses the holiday quarter is always the biggest). Then watch the trend across several years: is year-over-year revenue growth accelerating or fading; is net income growing at least as fast as revenue (expanding vs compressing margins)? One quarter is noise — the multi-quarter trend is the signal.
Unlock Valuation Analysis
Get fair value estimates from multiple valuation models and see whether a stock is undervalued or overvalued.
- Multi-model fair value estimates (P/E, DCF, EPS Growth)
- Undervalued/overvalued assessment with upside potential
- Compare fair values across methodologies
Unlock Full Analysis
Get the complete 10-year financial history with interactive charts and growth analysis.
Related Stocks
Amgen (AMGN)
Biotechnology
Returned $5.12B to shareholders via dividends and buybacks.
Boston Scientific (BSX)
Health Care Equipment
Net income surged 55.7% to $2.89B in FY2025.
Bristol Myers Squibb (BMY)
Pharmaceuticals
Danaher Corporation (DHR)
Life Sciences Tools & Services
Merck & Co. (MRK)
Pharmaceuticals
Pfizer (PFE)
Pharmaceuticals